UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 09, 2026 Perspective Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communicat ...

Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α-NET continues to be well-tolerated Updated efficacy analysis suggests durable disease control and deepening of tumor response per RECIST v1.1 in the first 23 patients in Cohort 2 and both patients in Cohort 1Objective response in 39% of patients in Cohort 2 regardless of SSTR2 expression profile, including one Cohort 2 patient who experienced an initial objective response pending confirmation since the prior ...

SEATTLE, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 14, 2026, at 2:15 p.m. PT. 44th Annual J.P. Morgan Healthcare Conference – Company PresentationDate: Wednes ...

Core Insights - Perspective Therapeutics, Inc. announced that updated data on its [Pb]VMT-α-NET program will be presented at the ASCO-GI Congress 2026, scheduled for January 8 to 10, 2026 [1][2] Group 1: Company Overview - Perspective Therapeutics is focused on developing advanced radiopharmaceutical treatments for various cancers, utilizing proprietary technology that employs the alpha-emitting isotope Pb to target cancer cells [4][5] - The company is conducting a multi-center, open-label, dose-escalation study of [Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors [3][4] Group 2: Clinical Data and Efficacy - As of the data cut-off date of September 12, 2025, safety findings from 55 patients indicated a favorable safety profile for [²¹²Pb]VMT-α-NET, with no dose-limiting toxicities or Grade 4 or 5 treatment-emergent adverse events reported [4][6] - Among 25 patients evaluated, 20 (80%) remained progression-free, and 8 patients achieved confirmed responses, all from Cohort 2, with a median follow-up of 41 weeks [6]

Summary of Perspective Therapeutics FY Conference Call Company Overview - **Company**: Perspective Therapeutics (NYSEAM:CATX) - **Focus**: Radiopharmaceuticals, specifically targeting various isotopes and chelator technologies for cancer treatment Key Industry Insights - **Radiopharmaceutical Market**: The field has evolved significantly over the past 30 years, moving from Iodine-131 to more advanced isotopes like Lutetium-177 and Actinium-225, which offer better targeting and efficacy [3][4] - **Emerging Isotopes**: Lead-212 is highlighted as a potent alpha emitter with significant potential for tumor destruction, alongside other isotopes like astatine and terbium [5][6] Core Product Development - **VMT-NET Program**: Targets SSTR2 positive tumors, showing a promising overall response rate (ORR) of 44% compared to Lutathera's 13% [12][15] - **Safety Profile**: VMT-NET has demonstrated a clean safety profile with no significant adverse events reported, which is crucial for patients with chronic conditions [19][14] - **Clinical Data**: Recent data presented at ESMO indicates strong therapeutic and clinical profiles, with a surge in physician interest for patient enrollment [13][22] Competitive Landscape - **Comparison with Competitors**: The VMT-NET program shows superior efficacy and safety compared to competitor programs from Sanofi and others, which reported lower ORR and safety concerns [20][21] - **Market Positioning**: The company aims to establish itself as a leader in the radiopharmaceutical space by addressing unmet medical needs and providing safer, more effective treatment options [11][12] Future Development and Regulatory Strategy - **FDA Engagement**: The company is actively preparing for discussions with the FDA regarding registrational trials, focusing on safety and efficacy data [24][41] - **Ongoing Trials**: The company is currently enrolling patients in multiple programs, with plans to present data at medical conferences next year [37][38] Financial Health - **Cash Runway**: The company has a cash runway extending until the end of 2026, with $172 million on the balance sheet and a historical burn rate of $20 million per quarter [41][42] - **Manufacturing Capacity**: Perspective Therapeutics has operational sites in Iowa and New Jersey, with additional facilities in development across major cities, enhancing its production capabilities [43] Additional Programs - **MC1R and FAP Programs**: The company is exploring innovative approaches to target melanoma and solid tumors, respectively, with promising preclinical data [30][32][35] Conclusion - **Strategic Vision**: Perspective Therapeutics is positioned to leverage its innovative radiopharmaceuticals to transform cancer treatment, focusing on safety, efficacy, and addressing significant unmet medical needs in oncology [29][31]

SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 – Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatDate: Tuesday ...

Group 1 - The management team of Perspective Therapeutics is open to questions from the audience, utilizing a QR code for submissions [1] - The focus of Perspective Therapeutics includes key clinical programs that are currently in development [2]

Financial Performance - Grant revenue for Q3 2025 was $209,000, a decrease of 43% compared to $369,000 in Q3 2024[15] - Total operating expenses for Q3 2025 were $28,070,000, up 48% from $19,003,000 in Q3 2024[15] - Net loss from continuing operations for Q3 2025 was $25,969,000, compared to a loss of $15,122,000 in Q3 2024, representing a 72% increase in losses[15] - The company reported a net loss of $65,631,000 for the nine months ended September 30, 2025, compared to a loss of $39,110,000 for the same period in 2024, reflecting a 68% increase in losses[17] - The company experienced a net loss of $25.969 million for the quarter ended September 30, 2025, compared to a net loss of $21.485 million for the previous quarter[30] - Total operating expenses for the nine months ended September 30, 2025, were $74.573 million, up from $47.122 million in 2024[15] Cash and Liquidity - Cash, cash equivalents, and restricted cash at the end of Q3 2025 were $26,762,000, down from $226,443,000 at the end of Q3 2024[17] - As of September 30, 2025, the company reported cash, cash equivalents, and short-term investments of $174.1 million, with a total accumulated deficit of $297.4 million[30] - The company plans to fund its operations into late 2026 with its current cash reserves, but may seek additional capital through various means[31] - The Company has $24.4 million in cash equivalents as of September 30, 2025, down from $59.7 million at the end of 2024[77] - The total cash equivalents and available-for-sale securities as of September 30, 2025, were $171.800 million, compared to $225.056 million as of December 31, 2024[80] Shareholder Activities - The total number of shares outstanding increased from 70,671,464 at December 31, 2024, to 74,337,990 at September 30, 2025, reflecting the issuance of common stock[19] - A 1-for-10 reverse stock split was executed on June 14, 2024, affecting all stockholders uniformly[28] - Share-based compensation expenses were $2.156 million for the quarter ended September 30, 2025[19] - The Company reported a basic and diluted loss per share, calculated by dividing net loss by the weighted average number of shares outstanding, which did not include potentially dilutive common stock equivalents[35] - As of September 30, 2025, there were 10,902,610 total potentially dilutive securities, compared to 7,667,413 as of September 30, 2024, indicating an increase of approximately 42.5%[36] Business Operations - The company has not generated revenue from commercial products and incurs the majority of its operating expenses in the United States[29] - The company has a single operating segment focused on radiopharmaceutical development, with no significant changes in accounting policies reported[29] - The company is focused on obtaining regulatory approvals for its future program candidates, including Fast Track designation for PSV359 from the FDA[8] - The company is leveraging technology to identify and develop future program candidates, aiming to enhance its competitive position in the market[8] Asset Management - As of September 30, 2025, the Company's property and equipment, net, was valued at $64.4 million, an increase from $57.3 million as of December 31, 2024[74] - The Company holds indefinite-lived intangible assets valued at $50.0 million, representing the estimated fair value of its pipeline of acquired radiotherapy program candidates[75] - The Company recognized a total gain from discontinued operations of $514,000 for the nine months ended September 30, 2025, while incurring a loss of $949,000 for the same period in 2024[69] Financing Activities - The Company entered into a 2024 ATM Agreement allowing for the sale of up to $250.0 million of Common Stock, with a commission of up to 3.0% on gross proceeds from each sale[39][40] - The Company raised approximately $10.2 million from the sale of 3,379,377 shares at an average price of $3.02 per share under the 2024 ATM Agreement on February 18, 2025[43] - The gross proceeds from the May 2024 Registered Offering were approximately $80.0 million, before underwriting discounts and commissions[45] - The Company completed a private placement on March 6, 2024, raising approximately $87.4 million from the sale of 9,200,998 shares at $9.50 per share[48] - The Company sold 5,634,235 shares to Lantheus for a total of $50.0 million, representing 19.99% of the outstanding shares as of January 8, 2024[51] Lease and Liability Management - The Company recognized a right-of-use asset and lease liability of approximately $1.1 million upon entering into a lease for lab and office space effective April 1, 2024[91] - The Company recognized a right-of-use asset and lease liability of approximately $0.6 million upon entering a lease for office space in Somerset, NJ, which terminates on November 30, 2028[93] - The Company entered into a lease with Unico Properties LLC for office space in Seattle, WA, recognizing a right-of-use asset and lease liability of approximately $0.8 million, terminating in October 2028[95] - The Company's operating lease expense was $0.3 million for the three months ended September 30, 2024, and $0.8 million for the nine months ended September 30, 2025[96] - The total future operating lease payments as of September 30, 2025, amount to $1.863 million, with a total lease liability of $1.675 million after accounting for imputed interest[97] Regulatory and Compliance - The company anticipates potential impacts from U.S. and international trade policies on costs for supplies and materials used in drug development[8] - The Company has accrued an estimated liability of $0.2 million related to settlement negotiations with stockholder plaintiff firms as of September 30, 2025[84] - The Company reduced its estimated liability for hazardous waste removal by $0.3 million, resulting in an estimated liability of $0.2 million as of September 30, 2025[98]

Core Insights - Perspective Therapeutics, Inc. is advancing its clinical programs in radiopharmaceuticals aimed at cancer treatment, with a focus on neuroendocrine tumors, melanoma, and solid tumors [2][24][25] Clinical Highlights - The company is conducting a multi-center, open-label study of [Pb]VMT-α-NET targeting SSTR2-positive neuroendocrine tumors, with interim data presented at major medical conferences [3][4][7] - Updated interim results show a favorable safety profile for [Pb]VMT-α-NET, with no dose-limiting toxicities reported and 80% of patients remaining progression-free [8][9] - Cohort 3 of the [Pb]VMT-α-NET study opened in June 2025, with patients receiving up to four doses every eight weeks [9][10] Financial Summary - As of September 30, 2025, the company had approximately $174 million in cash and short-term investments, down from $227 million at the end of 2024, which is expected to fund operations into late 2026 [7][16][17] - Research and development expenses increased by approximately 69% year-over-year for Q3 2025, totaling $20.3 million, primarily due to increased clinical activities and personnel costs [20] - The net loss for Q3 2025 was $26 million, or $0.35 per share, compared to a net loss of $15.1 million, or $0.21 per share, for the same period in 2024 [23][30] Operational Developments - The company has transitioned its operations to focus on continuing operations following the divestiture of its brachytherapy segment in April 2024 [18] - The company is also developing complementary imaging diagnostics to enhance treatment personalization and optimize patient outcomes [24] Future Outlook - The company anticipates sharing updates on its clinical-stage medicines throughout 2026, with strong patient recruitment and clinical site engagement [7][11] - Plans are in place to submit data from ongoing studies to medical conferences in the coming year [11][12]

Core Insights - Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on advanced cancer treatments using proprietary technology that employs the alpha-emitting isotope Pb for targeted radiation delivery to cancer cells [2][3] Company Overview - The company is pioneering advanced treatments for various cancers and is developing complementary imaging diagnostics that utilize the same targeting moieties, allowing for personalized treatment and optimized patient outcomes [2] - The "theranostic" approach enables visualization of specific tumors followed by targeted treatment, potentially improving efficacy and minimizing toxicity [2] Clinical Development - The company's neuroendocrine tumor (VMT-α-NET), melanoma (VMT01), and solid tumor (PSV359) programs are currently in Phase 1/2a imaging and therapy trials in the U.S. [3] - Perspective Therapeutics is expanding its regional network of drug product candidate finishing facilities, supported by its proprietary Pb generator, to provide patient-ready product candidates for clinical trials and commercial operations [3] Upcoming Events - Members of the senior leadership team will participate in the Truist Securities BioPharma Symposium on November 6, 2025, in New York, NY, for one-on-one meetings with investors [1] - The company will also be featured in a Fireside Chat at the UBS Global Healthcare Conference on November 11, 2025, from 4:15 to 4:50 p.m. ET in Palm Beach, FL [2]